# EDGAR Filing Document

**Accession Number:** 0002071320
**File Stem:** 0001847903-25-000085
**Filing Date:** 2025-6
**Character Count:** 9304
**Document Hash:** 1f63ac291e4116a5704425f2d71da8e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001847903-25-000085.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001847903-25-000085

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250527

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Deferiere Raphael
- **CENTRAL INDEX KEY:** 0002071320

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40445
- **FILM NUMBER:** 251019888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O CENTESSA PHARMACEUTICALS PLC
- **STREET 2:** 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM
- **CITY:** CHESHIRE
- **PROVINCE COUNTRY:** X0
- **ZIP:** WA14 2DT
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Centessa Pharmaceuticals plc
- **CENTRAL INDEX KEY:** 0001847903
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR
- **STREET 2:** 1 ASHLEY ROAD
- **CITY:** ALTRINCHAM, CHESHIRE
- **STATE:** X0
- **ZIP:** WA14 2DT
- **BUSINESS PHONE:** 44 7391 789784

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR
- **STREET 2:** 1 ASHLEY ROAD
- **CITY:** ALTRINCHAM, CHESHIRE
- **STATE:** X0
- **ZIP:** WA14 2DT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Centessa Pharmaceuticals Ltd
- **DATE OF NAME CHANGE:** 20210224

## Ex-24

```

Power of Attorney

	Know all by these presents, that the undersigned hereby makes, constitutes
and appoints each of Iqbal Hussain, Gregory Weinhoff, and Richard Menziuso,
or either of them acting singly, and with full power of substitution
and re-substitution, the undersigned's true and lawful attorney-in-fact
(each of such persons and their substitutes being referred to herein
as the "Attorney-in-Fact"), with full power to act for the undersigned
and in the undersigned's name, place and stead, in any and all capacities, to:
1.	Prepare, execute, and submit to the Securities and Exchange
Commission ("SEC") a Form ID, including amendments thereto, and any other
documents necessary or  appropriate to obtain codes and passwords enabling
the undersigned to make electronic filings with the SEC of reports required
or considered by the Attorney-in-Fact to be advisable under Section 13 or
Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act") or
any rule or regulation of the SEC;
2.	Prepare, execute and submit to the SEC, Centessa Pharmaceuticals plc,
a public limited company organized under the laws of England and
Wales (the "Company"), and/or any national securities exchange on which
the Company's securities are listed any and all reports (including any
amendments thereto) the undersigned is required to file with the SEC,
or which the Attorney-in-Fact considers it  advisable to file with the SEC,
under Section 13 or Section 16 of the Exchange Act or any rule or  regulation
thereunder, or under Rule 144 under the Securities Act of 1933 ("Rule 144"),
with respect to the any security of the Company, including Forms 3, 4 and 5,
Schedules 13D and 13G, and Forms 144; and
3.	Obtain, as the undersigned's representative and on the undersigned's behalf,
information regarding transactions in the Company's equity securities from
any third party, including the Company and any brokers, dealers, employee
benefit plan administrators and trustees, and the undersigned hereby authorizes
any such third party to release any such information to the Attorney-in-Fact.
	The undersigned acknowledges that:
a)	This Power of Attorney authorizes, but does not require, the
Attorney-in-Fact to act in his or her discretion on information provided
to such Attorney-in-Fact without independent verification of such information;
b)	Any documents prepared or executed by the Attorney-in-Fact on behalf
of the undersigned pursuant to this Power of Attorney will be in such form
and will contain such information as the Attorney-in-Fact, in his or
her discretion, deems necessary or desirable;
c)	Neither the Company nor the Attorney-in-Fact assumes any liability
for the undersigned's responsibility to comply with the requirements of
Section 13 or Section 16 of the Exchange Act or Rule 144, any liability
of the undersigned for any failure to comply with such requirements, or
any liability of the undersigned for disgorgement of profits under
Section 16(b) of the Exchange Act; and
d)	This Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigned's obligations
under Section 13 or Section 16 of the Exchange Act, including,
without limitation, the reporting requirements under Section 13 or
Section 16 of the Exchange Act.
	The undersigned hereby grants to the Attorney-in-Fact full power
and authority to do and perform each and every act and thing requisite,
necessary or advisable to be done in connection with the foregoing,
as fully, to all intents and purposes, as the undersigned might or could
do in person, hereby ratifying and confirming all that the Attorney-in-Fact,
or his or her substitute or substitutes, shall lawfully do or cause to be
done by authority of this Power of Attorney. The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against
any demand, damage, loss, cost or expense arising from any false or
misleading information provided by the undersigned to the attorneys-in-fact.
	This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 4 or 5 or
Schedules 13D or 13G or Forms 144 with respect to the undersigned's
holdings of and transactions in securities of the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
Attorney-in-Fact. This Power of Attorney revokes all previous powers of
attorney with respect to the subject matter of this Power of Attorney.
This Power of Attorney shall expire as to any individual attorney-in-fact
if such attorney-in-fact ceases to be an employee of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney
as of May 27, 2025.

/s/ Raphael Deferiere
Signature

Raphael Deferiere
Print Name

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Deferiere Raphael<br><sub>(Last) (First) (Middle)</sub><br>C/O CENTESSA PHARMACEUTICALS PLC<br>3RD FL., 1 ASHLEY RD, ALTRINCHAM<br><sub>(Street)</sub><br>CHESHIRE, X0 WA14 2DT<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Centessa Pharmaceuticals plc [ CNTA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-05-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Gregory Weinhoff, attorney-in-fact  
**Date:** 2025-06-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**